 |
Dr. Ralf Brandt, PhD
Chief Executive Officer & Managing Director
Dr. Brandt is the co-founder of vivoPharm. He is a biochemist and cell biologist with over 15 years experience in research programs of experimental oncology. Furthermore, he has immense experience in in vivo pharmacology and anti-cancer drug profiling. He received his Licence (BSc in Biochemistry and Animal Physiology) in 1986, and his PhD (in Biochemistry) in 1991 from the Martin-Luther University of Halle-Wittenberg, Germany. Dr. Brandt was employed at research positions at the National Cancer Institute in Bethesda, MD, USA and at Schering AG, Germany. Since 1990, Dr. Brandt has been active in the field of preclinical oncology. He led the Tumour Biology program at Novartis Pharma AG, Switzerland and established several transgenic mouse lines developing tumours under the control of oncogenes.
During Dr. Brandt's long career in the pharmaceutical industry he has acquired significant knowledge and expertise in leading business units and representation of services to the pre-clinical research market.
Dr. Brandt is a member of the Scientific Advisory Board at Receptor Inc. in Toronto Canada
|
 |
Dr. Katja Wosikowski, PhD
Head, vivoPharm Europe
Dr. Wosikowski completed her PhD in cell biology at the Biozentrum in Switzerland. She was awarded a post-doctoral fellowship at the National Institutes of Health in the US to study drug resistance mechanisms and growth factor signalling pathways.
Dr. Wosikowski is an expert in designing, managing, and reporting preclinical pharmacology studies and preparing dossiers for regulatory approval. She has over 10 years international experience in preclinical oncology and drug development and holds over 10 patents. She led the preclinical pharmacology laboratory at Klinge Pharma in Germany, and managed the small molecule urokinase inhibitor programme at Wilex AG. As Associate Director, Pharmacology, at GPC Biotech AG she was responsible for the pharmacology of the preclinical and clinical compounds in development.
|
 |
Sabine Brandt
Finance and Human Resources Manager
Mrs Sabine Brandt is a co-founder of vivoPharm. Her career, which has spanned close to 10 years, includes financial management, financial planning and sales in a variety of industry sectors such as insurance and banking. In these roles, Mrs Brandt has gained experience within various departments of the banking and financial markets in Germany. Mrs Brandt led in the establishment of new offices for some insurance companies which has brought her a high level of experience in accounting and sales.
|
| |
Dr Lorraine Mackenzie
Vice President, Science & Research
|
 |
Dr. Fernando Felquer PhD, MBA
Vice President, Business Development
Dr. Felquer received his Bachelor of Science (hons) from the University of Morn, Buenos Aires in 1998. Following graduation, he worked in the clinical diagnostics area for several years.
He moved to Adelaide in 2000, to work on the intracellular signaling pathways involved in disorders such as inflammation and cancer. After completing his PhD from the University of Adelaide in 2005 he worked on Stem Cell Biology and Developmental Genetics as a post-doctoral fellow at the University of Adelaide. He joined vivoPharm in March 2008 where he was responsible for the establishment of the in vitro pharmacology laboratory and vivoPharm's analytical facility at Thebarton, SA. Fernando took on the role of Vice President, Business Development and Science in October 2009. In his current role, he evaluates new technologies and opportunities that have the potential to expand vivoPharm's portfolio and deliver better value to our customers and shareholders.
|
| |
Dr. Melanie Keller, PhD
Project Manager
Dr. Keller completed her PhD at the Ludwig-Maximilian-University Munich. Within a cooperation with Klinikum Großhadern (Munich, Germany) she worked on projects investigating Ischemia/Reperfusion Injury and Endotoxemia. Dr. Keller then took a position at ECRON, a full service CRO, where she was responsible for preparation, monitoring and performance of clinical trials in Europe and US as a Clinical Research Associate (phase II and III). Prior to joining vivoPharm she worked at GPC Biotech AG managing international clinical trials (phase I-III). At vivoPharm Dr. Keller is responsible for the management of preclinical projects and study timelines for clients in Europe and U.S. East in close cooperation with the Study Coordinators. |
 |
Tina Vincent
Study Coordinator
Miss Vincent completed her Bachelor of Biotechnology at Flinders University in 2001, completing her Honours in the Department of
Haematology and Genetic Pathology. ÊPrior to joining vivoPharm in 2008, she was a research assistant for seven years. She has worked on small animal models investigating the molecular mechanisms of cancer cell drug resistance, and worked at the Institute of Medical and Veterinary Science in the Department of Orthopaedics, investigating molecular causes of bone diseases, including osteoporosis, and bone, breast and prostate cancers. Tina is responsible for study design and co-ordination, data monitoringÊthroughout study duration, as well as preparation of final study reports. |
 |
Chris Holding
Study Coordinator
Chris Holding completed his Bachelor of Biotechnology (Honours) degree in 1998 at Flinders University of South Australia, specialising in molecular biology and human disease. Prior to joining vivoPharm Chris worked as a Research Assistant for 10 years on NHMRC funded projects investigating inflammatory bone loss diseases. With significant experience in molecular based research and development of animal models of disease, Chris is responsible for study design and co-ordination, data monitoring throughout study duration, as well as preparation of final study reports. |
